🇺🇸 FDA
Patent

US 8080554

Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation

granted A61KA61K2039/55561A61K31/00

Quick answer

US patent 8080554 (Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Dec 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Dec 20 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
34
CPC classes
A61K, A61K2039/55561, A61K31/00, A61K31/365, A61K31/519